420 PROSTVAC in combination with nivolumab enhanced immune cell infiltration in prostate cancer
Shania Bailey(National Institutes of Health), James L. Gulley(National Cancer Institute), Jennifer L. Marté(National Cancer Institute), Peter A. Pinto(National Institutes of Health), Amy Hankin(National Institutes of Health), Wiem Lassoued(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Antonios Papanicolau‐Sengos(National Institutes of Health), Fatima Karzai(National Institutes of Health), Houssein Abdul Sater(National Institutes of Health), N. Williams(National Institute of Allergy and Infectious Diseases), Michell Manu(Frederick National Laboratory for Cancer Research), William L. Dahut(National Cancer Institute)
Cited by 4
Related Papers
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
|Cancer Immunology Research|2015|456
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
Current Landscape of Immunotherapy in Breast Cancer
|JAMA Oncology|2019|409
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371